United States
Polyclonal Antibody to DR3 (NT)
| PSC-1166-C020 | 20 µg | 87.00 USD |  |
||
| PSC-1166-C100 | 100 µg | 380.00 USD | |
||
Apoptosis, or programmed cell death, occurs during normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by certain cytokines including TNF and Fas ligand (CD95L) of the TNF family through their death domain containing receptors, TNFR-1 and Fas (CD95). A novel cell death receptor was identified by several groups independently and designated DR3, Wsl-1, Apo-3, TRAMP and LARD [1-5]. The ligand for this novel death receptor has been defined as TWEAK, also termed Apo3L.
|
FIGURES
 Figure: Western blot analysis of DR3 in Jurkat total cell lysate with anti-DR3 (NT) at 1:1000 dilution.
|
|||||||||||||||||||||||||||||||||||||||||
Product Literature References
LARD: a new lymphoid-specific death domain containing receptor regulated by alternative pre-mRNA splicing: G.R. Screaton, et al.; PNAS 94, 4615 (1997), Abstract; Full Text
TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95): J.L. Bodmer, et al.; Immunity 6, 79 (1997), Abstract;
A death-domain-containing receptor that mediates apoptosis: J. Kitson, et al.; Nature 384, 372 (1996), Abstract;
Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-kappa B: S.A. Marsters, et al.; Curr. Biol. 6, 1669 (1996), Abstract;
Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95: A.M. Chinnaiyan, et al.; Science 274, 990 (1996), Abstract;
another CS2 website
©2019 Axxora, LLC.,
